Delfi Diagnostics said the New York State Department of Health approved its FirstLook Lung laboratory-developed test, enabling the company to offer its cfDNA-based liquid biopsy screening assay across all 50 U.S. states. The company is also pursuing FDA authorization for the test. Delfi said evidence from a clinical study of nearly 3,000 patients showed FirstLook Lung raised screening rates by nearly threefold, framing the state clearance as an access milestone. The approval reduces a barrier to scaling coverage-dependent screening and provides a regulatory foothold ahead of federal review. For biotech and med-tech, the development underscores the growing market for blood-based lung cancer screening and the role of state-by-state pathways in accelerating clinical uptake.